Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pseudo-pharma VC Index signs five year manufacturing deal with Lonza

This article was originally published in Scrip

Executive Summary

In what may represent another nail in the coffin of the stand-alone biotech company model, pharma-backed venture capitalist Index Ventures has taken an "unusual" step of signing an exclusive agreement with a major contract manufacturing organization to develop and manufacture the biologics of all its portfolio companies. The move, which could be first of many, underlines Index’ asset-based investment approach in which the investor acts, in development at least, as a pseudo-pharmaceutical company.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC024053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel